Antimigraine agents: July 1995 - December 1996

Bibliography

• NOACK H, ROTHROCK JF: Migraine: definitions, mecha-nisms and treatment. Southern Med. J. (1996) 89(8):762–769.
   PubMedGoogle Scholar
• KELLEY RE: Effective migraine headache management. Inter. Med. (1996) 17(7):66–81.
   Google Scholar
• SKAER TL: Clinical presentation and treatment of mi-graine. Clin. Ther. (1996) 18(2):229–245.
   PubMedGoogle Scholar
• WORTHINGTON I: Current migraine therapy. Can. J Clin. Pharmacol (1996) 3(0:39–51.
   Google Scholar
• FERRARI MD, HAAN J: Acute treatment of migraine at-tacks. Curr. Opin. Neurol (1995) 8(3):237–242.
   PubMedGoogle Scholar
• RASMUSSEN BK: Epidemiology of migraine. Biomed. Pharmacother. (1995) 49(10):452–455.
   PubMedGoogle Scholar
• SILBERSTEIN SD, LIPTON RB: Headache epidemiology: emphasis on migraine. Neurol Clinics (1996) 14(2):421–434.
   PubMedGoogle Scholar
• HARRISON DL, COONS SJ, JONES WN, LABADIE EL: The economic impact of a protocol for the management of migraine headaches. J. Res. Pharm. Eco. (1996) 7(3):35–48.
   Google Scholar
• ENSINK FBM: The efficacy of sumatriptan in the acute treatment of migraine. Headache Quart. (1995) 6(4):280–292.
   Google Scholar
• WILKINSON M, PFAFFENRATH V, SCHOENEN J, DIENERHC, STEINER TJ: Migraine and cluster headache - their management with sumatriptan: a critical review of the current clinical experience. Cephalalgia (1995) 15(5)337–357.
   Google Scholar
• VISSER WH, DE VRIEND RHM, JASPERS NMWH, FERRARI MD: Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology (1996) 47 (1) 46–51.
   PubMed Web of Science ®Google Scholar
• HARRISON DL, SLACK MK: Meta-analytic review of the effect of subcutaneous sumatriptan in migraine head-ache. J. Pharm. Technol (1996) 12(3):109–114.
   Google Scholar
• VISSER WH, DE VRIEND RHM, JASPERS NMWH, FERRARI MD: Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia (1996) 16:554–559.
   PubMed Web of Science ®Google Scholar
• VISSER WH, BURGGRAAF J, MULLER LM et al: Pharmacok-inetic and pharmacodynamic profiles of sumatriptan in patients with headache recurrence or no response. Clin. Pharmacol Ther. (1996) 60(4):452–460.
   PubMedGoogle Scholar
• VANDENBRINK AM, BAR WA, FERRARI MD et al.: Aug-mented contraction of the human isolatedcoronary artery by sumatriptan: a possible role for endogenous thromboxane. Br. J. Pharmacol (1996) 119(5):855–862.
   PubMedGoogle Scholar
• RAPOPORT AM, SHEFTELL FD: Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs (1997) 7(1):37–46.
   Google Scholar
• VISSER WH, FERRARI MD, KLEIN KB, COX RC, JONES D: An in-patient placebo-controlled dose-ranging study of oral 311C90 in the acute treatment of migraine [Ab-stract]. Headache (1995) 35:292.
   Google Scholar
• KEMPSFORD RD, LACEY LF, KEENE ON, THOMAS M: The safety, tolerability and pharmacokinetics pf subcutane-ous GR85548, a novel 5-HT1 receptor agonist for the treatment of migraine [Abstract]. Br. J. Clin. Pharmacol (1993) 36:170.
   Google Scholar
• VISSER WH, TERWINDT GM, REINES SA et al: Rizatriptan vs. sumatriptan in the acute treatment of migraine: a placebo-controlled dose-ranging study. Arch. Neurol (1996) 53(10:1132–1137.
   Google Scholar
• JACKSON NC: A comparison of oral eletriptan (UK-1160,440) (20-80 mg) and oral sumatriptan (100 mg) in the treatment of migraine [Abstract]. Cephalalgia (1996) 16:368–369.
   Google Scholar
• KAMALI F, TOMMEY R, WALLACE RJ, CALVERT A, SOONS PA: The safety of sumatriptan administration 2 h after subcutaneous injection of alniditan, a new anti-mi-graine drug, in healthy volunteers [Abstract]. Br. J. Pharmacol. (1996) 41:456.
   Google Scholar
• SAXENA PR, FERRARI MD: Pharmacology of antimigraine 5-HT1D receptor agonists. Exp. Opin. Invest Drugs (1996) 5 (5):581–593.
   Google Scholar
• PAUVVELS PJ, PALMIER C, WURCH T, COLPAERT FC: Phar-macology of cloned human 5-HT1D receptor-mediated functional responses in stably transfected rat C6-glial cell lines: further evidence differentiating human 5-HT1n and 5-HT13 receptors. Naunyn Schmiedebergs Arch. Pharmacol. (1996) 353:144–156.
   PubMedGoogle Scholar
• ZGOMBICK JM, SCHECHTER LE, ADHAM N et al Pharma- cological characterizations of recombinant human 5-HT1Da and 5-HT1Db receptor subtypes coupled to adenylate cyclase inhibition in clonal cell lines; appar- ent differences in drug intrinsic eficacies between human 5-HT1p subtypes. Naunyn Schmiedebergs Arch. Pharmacol (1996) 354:226–236.
   PubMedGoogle Scholar
• HARTIG PR, HOYER D, PATRICK PA, HUMPHREY PA, MARTIN GR: Alignment of receptor nomenclature with the human genome: classification of 5-HT1s and 5-HT ID receptor subtypes. Trends Pharmacol Sci. (1996) 17:103–105.
   PubMed Web of Science ®Google Scholar
• HUMPHREY PP, GOADSBY PJ: The mode of action of sumatriptan is vascular? A debate. Cephalalgia (1994) 14(6):401–410.
   PubMed Web of Science ®Google Scholar
• BEATTIE DT, CONNOR HE: The pre- and postjunctional activity of CP-122, 288 a conformationally restricted analogue of sumatriptan. Eur. J. Pharmacol. (1995) 276:271–276.
   PubMed Web of Science ®Google Scholar
• LEE MS, MOSKOWITZ MA: Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 ex-hibit enhanced potency against neurogenic inflamma-tion in dura matter. Brain Res. (1993) 626:303–305.
   PubMed Web of Science ®Google Scholar
• OLLESEN J, THOMSEN LL, LASSEN LH, OLESEN IJ: The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia (1995) 15:94–100.
   PubMedGoogle Scholar
• FOZARD JR: The 5-Hydroxytryptamine-nitric oxide con-nection: the key link in the initiation of migraine? Arch. Int. Pharmacodyn (1995) 329:111–119.
   PubMedGoogle Scholar
• IVERSEN HK, OLESEN J: Headache induced by a nitric oxide donor (nitroglycerine) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia (1996) 16(6):412–418.
   PubMedGoogle Scholar
• GALLAI V, FLORIDI A, et aL: L-Arginine/nitric oxide pathway activation in patients of migraine patients with and without aura. Acta Neurol. Scand. (1996) 94(2):151–160.
   PubMedGoogle Scholar
• BEATTIE DT, CONNOR HE, HAGAN RM: Recent develop-ments in tachykinin NKi receptor antagonists: pros-pects for the treatment of migraine headache. Can. J. PhysioL PharmacoL (1995) 73:871–877.
   PubMed Web of Science ®Google Scholar
• GHELARDINI C, GALEOTTI N, FIGINI et aL: The central cholinergic system has a role in the antinociception induced in rodents and guinea-pigs by the antimigraine drug sumatriptan. J. PharmacoL Exp. Ther. (1996) 279(2):884–890.
   PubMedGoogle Scholar
• DIENER HC, FOH M, IACCARINO C et aL: Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. Cephalalgia (1996) 16(6) :441–447.
   PubMedGoogle Scholar